Invex Therapeutics (ASX:IXC) Total Equity: A$4.55 Mil (As of Dec. 2025)


ASX:IXC Invex Therapeutics Ltd ASX:IXC
37 GF Score
Price A$0.10
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Total Equity?

Invex Therapeutics ASX:IXC -9.09% 37 Total Equity is A$4.55 Mil as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Invex Therapeutics's total equity for the quarter that ended in Dec. 2025 was A$4.55 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Invex Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Total Equity Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial 32.08 28.48 21.23 5.69 5.25

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.30 5.69 5.38 5.25 4.55
ASX:IXC
37GF Score
Invex Therapeutics Ltd ASX:IXC
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Invex Therapeutics's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=5.468-0.221
=5.25

Invex Therapeutics's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=4.723-0.176
=4.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$4.55 Mil mean?
Invex Therapeutics (ASX:IXC) has a Total Equity of A$4.55 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Invex Therapeutics and its competitors.
Is Invex Therapeutics' Total Equity too high?
Invex Therapeutics' current Total Equity is A$4.55 Mil. Overall, Invex Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Total Equity compare to VRTX and REGN?
Invex Therapeutics' Total Equity of A$4.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Invex Therapeutics and its competitors. Invex Therapeutics's current Total Equity is A$4.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Total Equity of A$4.55 Mil. The current Total Equity is A$4.55 Mil. Invex Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Total Equity is A$4.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
37GF Score

Get the complete analysis for ASX:IXC

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.10
Price